AG
MRTX

Artal Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Artal Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-500,000
Closed -$29.4M – 130
2023
Q4 		$29.4M Sell
500,000
-200,000
-29% -$11.2M 0.98% 16
2023
Q3 		$30.5M Buy
700,000
+450,000
+180% +$16.1M 1.31% 14
2023
Q2 		$9.03M Buy
+250,000
New +$10.3M 0.28% 54
2023
Q1 		– Sell
-500,000
Closed -$22.7M – 150
2022
Q4 		$22.7M Buy
+500,000
New +$32.4M 1.26% 24

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Artal Group's MRTX Position: Q4 2023 in Review

Artal Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 2,024,226 shares — an estimated $114M sold.

Artal Group first reported a position in MRTX in Q4 2013 and held it in 24 quarters. The position peaked at $212M in Q3 2021. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Artal Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Artal Group sold 2,024,226 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $114M.
  • Artal Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2013 and held it in 24 quarters.
  • Artal Group's Mirati Therapeutics, Inc. Common Stock position peaked at $212M in Q3 2021.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.